LinqMed
Latest round
- Series B
Last raised
- May 2025
Total raised
- $34M
Investors
- 16
About LinqMed
Founded in 2022 and based in Chiba, Japan, LinqMed Inc. operates as a developer of cancer treatment that uses radioactive copper which can be traced through a PET scan. In April 2025, LinqMed Inc. The company offers treatment and drugs for cancer patients using copper isotopes. The firm has developed radiopharmaceuticals using copper radioisotope that can be used in the diagnosis of cancer as well as in treatment.
Who invested in LinqMed
16 investors across 4 rounds
See all investors in LinqMed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LinqMed
Who invested in LinqMed?
LinqMed has 16 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LinqMed raised?
LinqMed has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did LinqMed last raise money?
LinqMed's most recent round on record is a Series B, in May 2025.
What does LinqMed do?
Founded in 2022 and based in Chiba, Japan, LinqMed Inc.
Where is LinqMed headquartered?
LinqMed is headquartered in Tokyo, Japan.
Which VCs invest in companies like LinqMed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back healthcare specialists companies at LinqMed's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series B
Raising like LinqMed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.